Drug Profile


Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator 3E Therapeutics
  • Developer Ora Inc
  • Class Antiallergics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Allergic rhinitis

Most Recent Events

  • 04 Mar 2016 Efficacy data from a phase I/II trial in Allergic rhinitis presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 29 Mar 2015 Phase-I/II clinical trials in Allergic rhinitis in USA (Topical) (NCT02377895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top